Since first‐line chemotherapeutic strategies (gemcitabine plus nab‐paclitaxel or fluorouracil‐based FOLFIRINOX) have shown limited effects in prolonging the lifespan of pancreatic cancer patients, Olaparib has been used in the clinic to treat pancreatic cancer patients with BRCA1/2 mutations [28]; these patients are sensitive to PARP inhibitors. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.